Atorolimumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific immune pathways. It is classified as an immunomodulator and is primarily investigated for its potential in treating autoimmune diseases, particularly rheumatoid arthritis. The mechanism of action involves binding to certain proteins in the immune system, thereby modulating the inflammatory response. Atorolimumab is characterized by its high specificity and affinity for its target, which helps in reducing the symptoms associated with autoimmune conditions. The substance is typically administered via injection and may have a range of pharmacokinetic properties, including a specific half-life and distribution profile in the body. As with many biologics, potential side effects may include immune reactions, injection site reactions, and increased susceptibility to infections. Ongoing clinical trials and research continue to evaluate its efficacy and safety profile in various patient populations. Overall, Atorolimumab represents a significant advancement in targeted therapies for managing chronic inflammatory diseases.

Atorolimumab

202833-08-7: Atorolimumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific immune pathways. It is classified as an immunomodulator and is primarily investigated for its potential in treating autoimmune diseases, particularly rheumatoid arthritis. The mechanism of action involves binding to certain proteins in the immune system, thereby modulating the inflammatory response. Atorolimumab is characterized by its high specificity and affinity for its target, which helps in reducing the symptoms associated with autoimmune conditions. The substance is typically administered via injection and may have a range of pharmacokinetic properties, including a specific half-life and distribution profile in the body. As with many biologics, potential side effects may include immune reactions, injection site reactions, and increased susceptibility to infections. Ongoing clinical trials and research continue to evaluate its efficacy and safety profile in various patient populations. Overall, Atorolimumab represents a significant advancement in targeted therapies for managing chronic inflammatory diseases.

<p>Atorolimumab (P3x22914G4), a monoclonal antibody, is employed in immunotherapies that target the programmed death-1 (PD-1) receptor [1].</p>

<p>Anti-TNF alpha monoclonal antibody; used in the treatment of rheumatoid arthritis and Crohn's disease</p>

CAS 202833-08-7

Atorolimumab

Atorolimumab

Ref: TM-T76912

Atorolimumab

Ref: 3D-CLA1230